SITE005-0001

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-02-11

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-04 (study day 36); relationship: N

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-04-07 (study day 39); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 77); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: UNKNOWN; onset 2022-08-17 (study day 171); relationship: N

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 244); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-06-09 (study day 467); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 539); relationship: N

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-01 (study day 551); relationship: N

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-02 (study day 552); relationship: not assessed

Data queries

No data queries.